Get started
Work

Supplementary Figure 3 from Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Year: 2023
Type: supplementary-materials
Abstract: Figure S3 displays probability of overall survival over time in the study population
DOI: 10.1158/1078-0432.22480014
Authors: Matthew S. Davids, Bryone J. Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S. Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, Ulrich Jäger
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361815390
Cites:
Cited by:
Related to: 10